Maxcyte
NASDAQ: MXCTUnicorn · $1.3BGaithersburg, US · Delaware corporation · 1 known investors
Find your way into Maxcyte
MaxCyte develops non-viral electroporation and cell-engineering technology used to transfect and engineer cells for research and therapeutic development. It also offers gene editing risk assessment services and licensing partnerships to help cell and gene therapy developers advance toward clinical and commercial stages.
Founders & leadership
DA
Douglas A. DoerflerFounder
MV
Madhusudan V PeshwaExecutive
RE
Ronald E. HoltzExecutive
TR
Thomas RossExecutive
KD
Karen DonatoExecutive
Board
WB
William BrookeBoard director
SD
Sinclair DunlopBoard director
DD
Dennis DoughertyBoard director
JS
J. Stark ThompsonBoard director
AM
Arthur M MandellBoard director
JJ
John JohnstonBoard director
SC
Stanley C ErckBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 2 rounds · 2014–2016
▶$760.3KraisedSep 2016 · 9 investors · BiotechnologyRule 506(b)
▶$760.3KraisedSep 2016 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Madhusudan V PeshwaExecutive Officer
- J Stark ThompsonDirector
- Douglas A DoerflerExecutive Officer, Director
- Arthur M MandellDirector
- John JohnstonDirector
- Stanley C ErckDirector
- Ronald E HoltzExecutive Officer, Director
- Thomas RossExecutive Officer
- William BrookeDirector
- Offering amount
- $760.3K
- Amount sold
- $760.3K
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedDec 2014 · 21 investors · BiotechnologyRule 506(b)
▶$1.7MraisedDec 2014 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arthur MandellDirector
- Sinclair DunlopDirector
- Will BrookeDirector
- Madhusudan PeshwaExecutive Officer
- Dennis DoughertyDirector
- J. Stark ThompsonDirector
- Stan ErckDirector
- Douglas A. DoerflerExecutive Officer, Director
- Ronald E. HoltzExecutive Officer
- Karen DonatoExecutive Officer
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$1.3Bvaluation at IPOJul 2021 · $13.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Maxcyte do?
- MaxCyte develops non-viral electroporation and cell-engineering technology used to transfect and engineer cells for research and therapeutic development. It also offers gene editing risk assessment services and licensing partnerships to help cell and gene therapy developers advance toward clinical and commercial stages.
- Who founded Maxcyte?
- Maxcyte was founded by Douglas A. Doerfler.
- Who are Maxcyte's investors?
- Maxcyte's investors include Sofinnova Partners.
- How much funding has Maxcyte raised?
- Maxcyte has disclosed $2.5M raised across 2 rounds.
- Where is Maxcyte headquartered?
- Maxcyte is headquartered in Gaithersburg, US.